Why the study?
Does glycopyrronium improve cardiovascular stability and reduce adverse cardiac events compared to atropine during reversal of neuromuscular blockade in patients with cardiovascular disease?
Does glycopyrronium improve cardiovascular stability and reduce adverse cardiac events compared to atropine during reversal of neuromuscular blockade in patients with cardiovascular disease?
Glycopyrronium is a safer and more suitable agent than atropine for the reversal of neuromuscular blockade in patients with cardiovascular disease due to better hemodynamic stability and fewer dysrhythmias.
Answers are grounded in this paper and cite their sources.
Supports preferring glycopyrronium over atropine for reversal in cardiovascular disease; confirms superior stability and fewer ischemic events in this RCT.
The effects of atropine and glycopyrronium, when given intravenously with neostigmine during the reversal of neuromuscular blockade in patients with cardiovascular disease, were compared in a double blind trial. Atropine was associated with a significantly greater elevation of heart rate and rate-pressure product than glycopyrronium. This elevation was also more sustained with atropine. The entire atropine population also showed a significantly greater incidence of ST-segment depression on the electrocardiogram than that observed in those who had received glycopyrronium. Furthermore, patients with ischaemic heart disease and previous myocardial infarction who received atropine showed a significantly greater incidence of dysrhythmias than those given glycopyrronium. It is suggested that at the time of reversal of neuromuscular blockade in patients with cardiovascular disease, glycopyrronium is a more suitable agent than atropine.
No takes yet. Share an insight, caveat, or question.
Mostafa et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: